United Europeans for development of pharmacogenomics in multiple sclerosis network

Pharmacogenomics

Volumn 10, Issue 5, 2009, Pages 885-894

  Vandenbroeck, Koen ^a   Comabella, Manuel ^b   Tolosa, Eva ^c   Goertsches, Robert ^d   Brassat, David ^e   Hintzen, Rogier ^f   Infante Duarte, Carmen ^g   Favorov, Alexander ^h,m   Escorza, Sergio ⁱ   Palacios, Ricardo ^j   Oksenberg, Jorge R ^k   Villoslada, Pablo ^l  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e INSERM   (France)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Progenika   (Spain)

^j Digna Biotech   (Spain)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^m STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

more..

Author keywords

Interferon; Multiple sclerosis; Pharmacogenomics; Proteomics; Systems biology; Training

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; GLATIRAMER;

ARTICLE; BIOINFORMATICS; BIOMEDICINE; DISEASE MARKER; EUROPE; GENETICS; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOMODULATION; INTERNATIONAL COOPERATION; MEDICAL EDUCATION; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; PATENT; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PROTEOMICS; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; VALIDATION PROCESS;

ETHICS, MEDICAL; EUROPE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTELLECTUAL PROPERTY; INTERNET; MULTIPLE SCLEROSIS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RESEARCH; RNA, MESSENGER;

EID: 66849106883     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.33     Document Type: Article

References (34)

1. Infante-Duarte C, Waiczies S, Wuerfel J, Zipp F: New developments in understanding and treating neuroinflammation. J. Mol. Med. 86(9), 975-985 (2008).
2. Sospedra M, Martin R: Immunology of multiple sclerosis. Annu. Rev. Immunol. 23, 683-747 (2005).
3. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL: The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 9(7), 516-526 (2008).
4. Sobocki P, Pugliatti M, Lauer K, Kobeltz G: Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Multiple Scler. 13, 1054-1064 (2007).
5. Orton SM, Herrera BM, Yee IM et al.: Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 5(11), 932-936 (2006).
6. Martinez-Forero, I, Pelaez A, Villoslada P: Pharmacogenomics of multiple sclerosis: in search for a personalized therapy. Expert Opin. Pharmacother. 9(17), 3053-3067 (2008).
7. Menge T, Weber MS, Hemmer B et al.: Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 68(17), 2445-2468 (2008).
8. Lutterotti A, Martin R: Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 7(6), 538-547 (2008).
9. Vandenbroeck K, Mature C: Pharmacogenomics of the response to IFN-β in multiple sclerosis: ramifications from the first genome-wide screen. Pharmacogenomics 9(5), 639-645 (2008).
10. Villoslada P, Barcellos LF, Rio J et al.: The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β. J. Neuroimmunol. 130(1-2), 194-201 (2002).
11. Cunningham S, Graham C, Hutchinson M et al.: Pharmacogenomics of responsiveness to interferon IFN-β treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin. Pharmacol. Ther. 78(6), 635-646 (2005).
12. Byun E, Caillier SJ, Montalban X et al.: Genome-wide pharmacogenomic analysis of the response to interferon β therapy in multiple sclerosis. Arch. Neurol. 65(3), 337-344 (2008).
13. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E: Defining interferon β response status in multiple sclerosis patients. Ann. Neurol. 56(4), 548-555 (2004).
14. Leyva L, Fernández O, Fedetz M et al.: IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-β treatment response. J. Neuroimmunol. 163(1-2), 165-171 (2005).
15. Martínez A, de las Heras V, Mas Fontao, A et al.: An IFNG polymorphism is associated with interferon-β response in Spanish MS patients. J. Neuroimmunol. 173(1-2), 196-199 (2006).
16. Weinstock-Guttman B, Tamaño-Blanco M, Bhasi K, Zivadinov R, Ramanathan M: Pharmacogenetics of MXA SNPs in intefferon-β treated multiple sclerosis patients. J. Neuroimmunol. 182(1-2), 236-239 (2007).
17. Sriram U, Barcellos LF, Villoslada P et al.: Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun. 4(2), 147-152 (2003).
18. Fernández O, Fernández V, Mayorga C et al. HLA class II and response to interferon-β in multiple sclerosis. Acta Neurol. Scand. 112(6), 391-394 (2005).
19. Wergeland S, Beiske A, Nyland H et al.: IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur. J. Neurol. 12(3), 171-175 (2005).
20. Baranzini SE, Mousavi P, Rio J et al.: Transcription-based prediction of response to IFN-β using supervised computational methods. PLoS Biol. 3(1), E2 (2005).
21. Fernald GH, Knott S, Pachner A et al.: Genome-wide network analysis reveals the global properties of IFN-β immediate transcriptional effects in humans. J. Immunol. 178(8), 5076-5085 (2007).
22. Wandinger KP, Lünemann JD, Wengert O et al.: TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-β treatment in multiple sclerosis. Lancet 361(9374), 2036-2043 (2003).
23. Muraro PA, Liberati L, Bonarmi L et al.: Decreased integrin gene expression in patients with MS responding to interferon-β treatment. J. Neuroimmunol. 150(1-2), 123-131 (2004).
24. Soilu-Hänninen M, Laaksonen M, Hänninen A, Erälinna JP, Panelius M: Downregulation of VLA-4 on T cells as a market of long term treatment response to interferon β-1a in MS. J. Neuroimmunol. 167(1-2), 175-182 (2005).
25. Weinstock-Guttman B, Bhasi Y, Badgett D et al.: Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: relationships to 5-year clinical outcomes in multiple sclerosis patients. J. Neuroimmunol. 205, 113-125 (2008).
26. Stürzebecher S, Wandinger KP, Rosenwald A et al.: Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis. Brain 126(Pt 6), 1419-1429 (2003).
27. Malucchi S, Gilli F, Caldano F et al.: Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 70(13 Pt 2), 1119-1127 (2008).
28. Bartosik-Psujek H, Stelmasiak Z: The interleukin-10 levels as a potential indicator of positive response to interferon β treatment of multiple sclerosis patients. Clin. Neurol. Neurosurg. 108(7), 644-647 (2006).
29. Millonig A, Dressel A, Bahner D et al.: MxA protein - an interferon β biomarker in primary progressive multiple sclerosis patients. Eur. J. Neurol. 15(8), 822-826 (2008).
30. Nakatsuji Y, Nakano M, Moriya M et al.: Beneficial effect of interferon-β treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-β injection. Cytokine 36(1-2), 69-74 (2006).
31. O'Doherty C, Villoslada P, Vandenbroeck K: Pharmacogenomics of type I interferon therapy: a survey of response-modifying genes. Cytokine Growth Factor Rev. 18(3-4), 211-222 (2007).
32. Favorov AV, Andreewski TV, Sudomoina MA, Favorova OO, Parmigiani G, Ochs MF: A Markov chain Monte Carlo technique for identification of combinations of allelic variants underlying complex diseases in humans. Genetics 171(4), 2113-2121 (2005).
33. Villoslada P, Steinman L, Baranzini SE: Systems biology and its application to the understanding of neurological diseases. Ann. Neurol. 65(2), 124-139 (2009).
34. Daly AK: Individualized drug therapy. Curr. Opin. Drug Discov. Devel. 10(1), 29-36 (2007).